Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02321111 · ClinicalTrials.gov registry record · Phase 2
The Role of TLR4 on Lipid-induced Insulin Resistance
A Phase 2 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02321111 is a Phase 2 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 10 participants.
The verdict
NCT02321111, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether pharmacologic inhibition of Toll-like receptor 4 (TLR4) with eritoran for injection (E5564) prevents lipid-induced insulin resistance in lean, normal glucose tolerant (NGT) subjects.
Interventions
- DRUG Eritoran
- DRUG D5W (5% Dextrose in water)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-01 |
| Est. Completion | 2018-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02321111
The ClinicalTrials.gov registry entry for NCT02321111 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Eritoran is the first listed.
NCT02321111 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02321111 about?
NCT02321111 is a clinical study titled "The Role of TLR4 on Lipid-induced Insulin Resistance". The purpose of this study is to determine whether pharmacologic inhibition of Toll-like receptor 4 (TLR4) with eritoran for injection (E5564) prevents lipid-induced insulin resistance in lean, normal glucose tolerant (NGT) subjects.
What is the current status of trial NCT02321111?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2015-01. Estimated completion is 2018-09.
What interventions are being tested in trial NCT02321111?
The interventions under investigation include: Eritoran (DRUG), D5W (5% Dextrose in water) (DRUG).
Who is sponsoring clinical trial NCT02321111?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.